US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Evommune (EVMN) priced at $16.00 and opened at $17.25, closing its debut session above issue, outperforming expectations with steady aftermarket support.</li>
<li>The IPO was led by long-only and healthcare-dedicated investors, signaling conviction in the company’s focused dermatology pipeline.</li>
<li>Backing from RA Capital and a strong Phase 2 data set for EVO756 reinforce credibility and set the stage for continued positive momentum.</li>
</ul>


Evommune (EVMN) priced at $16.00 and opened at $17.25, closing its debut session above issue, outperforming expectations with steady aftermarket support.
The IPO was led by long-only and healthcare-dedicated investors, signaling conviction in the company’s focused dermatology pipeline.
Backing from RA Capital and a strong Phase 2 data set for EVO756 reinforce credibility and set the stage for continued positive momentum.


Evommune (EVMN) Jumps 26% on First Day, Capping Well-Received Biotech IPO

<ul>
<li>Lead asset EVO756 shows promising Phase 2 data in symptomatic dermographism, validating its MRGPRX2-targeting mechanism and supporting further expansion into atopic dermatitis.</li>
<li>A $115M Series C co-led by RA Capital and Sectoral Asset Management strengthens credibility and provides funding for multiple Phase 2 clinical programs.</li>
<li>Evommune’s IPO is multiple-times oversubscribed, driven by significant demand from healthcare-dedicated investors and mutual funds, signaling robust institutional interest.</li>
</ul>


Lead asset EVO756 shows promising Phase 2 data in symptomatic dermographism, validating its MRGPRX2-targeting mechanism and supporting further expansion into atopic dermatitis.
A $115M Series C co-led by RA Capital and Sectoral Asset Management strengthens credibility and provides funding for multiple Phase 2 clinical programs.
Evommune’s IPO is multiple-times oversubscribed, driven by significant demand from healthcare-dedicated investors and mutual funds, signaling robust institutional interest.


Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

<ul>
<li>Evommune (EVMN US) is set to offer 9.375 million shares at $15-$17 and is slated for a debut of November 6th on the NYSE.</li>
<li>According to the prospectus, the underwriters have reserved up to 5% of the shares at the initial public offering price in a directed share program.</li>
<li>The company has a handful of license agreements which could boost the profile of this biotech. </li>
</ul>


Evommune (EVMN US) is set to offer 9.375 million shares at $15-$17 and is slated for a debut of November 6th on the NYSE.
According to the prospectus, the underwriters have reserved up to 5% of the shares at the initial public offering price in a directed share program.
The company has a handful of license agreements which could boost the profile of this biotech. 


Evommune Inc. (EVMN): Chronic Inflammatory Biotech Sets Terms Seeking up to $511m Valuation

<ul>
<li>Evommune is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases.</li>
<li>Their most advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons.</li>
<li>The company is backed by many well-known sector dedicated investors including RA Capital. </li>
</ul>


Evommune is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases.
Their most advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons.
The company is backed by many well-known sector dedicated investors including RA Capital. 


Evommune Inc. (EVMN): Peeking at the IPO Prospectus of a Chronic Inflammatory Biotech Company

United States

Evommune, Inc.operates as a clinical-stage biotechnology company. The Company focuses on the developing therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Evommune serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Evommune (EVMN US)

Evommune (EVMN) Jumps 26% on First Day, Capping Well-Received Biotech IPO

Evommune (EVMN) IPO exceeds expectations, opening at $17.25 and closing above issue price with strong investor support and promising Phase 2 data.

IPO Boutique

Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

Phase 2 data for EVO756 in dermographism leads to successful $115M Series C funding and oversubscribed IPO for Evommune, signaling strong...

IPO Boutique

Evommune Inc. (EVMN): Chronic Inflammatory Biotech Sets Terms Seeking up to $511m Valuation

Biotech company Evommune (EVMN US) to offer 9.375 million shares at $15-$17, debuting on NYSE Nov 6 with potential boost from license agreements.

IPO Boutique

Evommune Inc. (EVMN): Peeking at the IPO Prospectus of a Chronic Inflammatory Biotech Company

Evommune is a biotech company developing therapies for chronic inflammatory diseases, with a focus on their advanced product candidate EVO756...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Evommune (EVMN) Jumps 26% on First Day, Capping Well-Received Biotech IPO

​Evommune (EVMN) IPO exceeds expectations, opening at $17.25 and closing above issue price with strong investor support and promising Phase 2 data.

IPO Boutique

Evommune Inc. (EVMN): RA Capital Backed Biotech Tests the IPO Market

Phase 2 data for EVO756 in dermographism leads to successful $115M Series C funding and oversubscribed IPO for Evommune, signaling strong...

IPO Boutique

Evommune Inc. (EVMN): Chronic Inflammatory Biotech Sets Terms Seeking up to $511m Valuation

​Biotech company Evommune (EVMN US) to offer 9.375 million shares at $15-$17, debuting on NYSE Nov 6 with potential boost from license agreements.

IPO Boutique

Evommune Inc. (EVMN): Peeking at the IPO Prospectus of a Chronic Inflammatory Biotech Company

​Evommune is a biotech company developing therapies for chronic inflammatory diseases, with a focus on their advanced product candidate EVO756...

IPO Boutique

Evommune (EVMN) IPO exceeds expectations, opening at $17.25 and closing above issue price with strong investor support and promising Phase 2 data.

Biotech company Evommune (EVMN US) to offer 9.375 million shares at $15-$17, debuting on NYSE Nov 6 with potential boost from license agreements.

Evommune is a biotech company developing therapies for chronic inflammatory diseases, with a focus on their advanced product candidate EVO756...